The gut microbiota is very specific to an individual and variable in time. Over the last few decades, it has been established that the complex interaction between the host and the multitude of organisms that compose the intestinal microbiota plays an important role in human metabolic health and disease. By combining with other targets and technologies, the tests and analytes based on gut microbiome has great potential to become diagnostic tools to improve the sensitivity and specificity for earlier colorectal cancer diagnoses. It also provides a perspective on their potential as biotherapeutics or agents in the management and treatment of IBD or gut infections like Clostridium difficile. The AML research and development team extends the usage of our SupFecal™ technologies, combining our unique processes for target enrichment and interferences/inhibitors removal/depletion, which eases gut microbiome profiling and quantitation for the purpose of health evaluation and aids with cancer diagnosis.